Turn Therapeutics Inc.

Stage 2 · Advancing · week 13

As of Oct 22, 2026, Turn Therapeutics is in Stage 2, the uptrend phase, now in week 13 (since Jul 27, 2026). It closed at $10.18, 33.6% below its 52-week high and above its 200-day average, which is rising.

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. More about the company

$10.18

+0.30% today

$309M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is TTRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-10-08 → 2026-10-22

S? 41w

S2 13w

2025-10-082026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S2 13w current

Total tracked: 54 weeks across 2 stage runs.

TTRX among Biotechnology35th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…35	TTRXTurn Therapeutics Inc.	Stage 2 · wk 13	96	−24.6%

vs 52W High

-33.6%

$2.71 lo$15.34 hi

33.6% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 13

1w13w26w

Week 13, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

49.2%

200 DMA: $6.82 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.99x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-24.6%

+19.2%

+203.9%

YTD

+117.1%

+114.8%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S2

Wk 13 · Vol 0.99x

2026-10-21S2

Wk 13 · Vol 0.45x

2026-10-20S2

Wk 13 · Vol 0.68x

2026-10-19S2

Wk 12 · Vol 0.26x

2026-10-16S2

Wk 12 · Vol 0.92x

2026-10-15S2

Wk 12 · Vol 0.71x

2026-10-14S2

Wk 12 · Vol 0.47x

2026-10-13S2

Wk 12 · Vol 1.05x

2026-10-12S2

Wk 11 · Vol 0.41x

2026-10-09S2

Wk 11 · Vol 0.99x

2026-10-08S2

Wk 11 · Vol 1.00x

2026-10-07S2

Wk 11 · Vol 1.63x

Moving averages & range

50 DMA

$11.63

200 DMA

$6.82

52W High

$15.34

52W Low

$2.71

5D Low

$10.15

Resistance levels (recent highs)

20d High

$14.39

60d High

$15.34

120d High

$15.34

250d High

$15.34

Next resistance

+41.4%

to 20d High

ROE

-686.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 442.6

Turn Therapeutics: quick answers

What stage is Turn Therapeutics in?

As of Oct 22, 2026, Turn Therapeutics (TTRX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 27, 2026 and is in week 13. What the four stages mean

Is Turn Therapeutics in an uptrend?

Yes. Turn Therapeutics is in a Stage 2 uptrend. It trades 49.2% above its 200-day average, which is rising.

How far is Turn Therapeutics from its 52-week high?

Turn Therapeutics closed at $10.18 on Oct 22, 2026, 33.6% below its 52-week high of $15.34. Its 52-week low is $2.71.

How has Turn Therapeutics performed over the past year?

As of Oct 22, 2026, Turn Therapeutics is up 114.8% over the past year and up 117.1% so far in 2026.

Which sector and industry is Turn Therapeutics in?

Turn Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.